Judge dismisses Teva suit on generic Restasis against FDA
Teva (TEVA) had previously filed a suit against the FDA dealing with its first generic version of Allergan’s (AGN) dry-eye drug Restasis in the District of Columbia U.S. district court in November of 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.